Immunocore Holdings: Pay

Immunocore Holdings paid its 3 named executives $20.3M in total in FY2025 (Dec). CEO Bahija Jallal, Ph.D. was paid $10.9M of that.

Pay$100 in the stock at the end of FY21 → $101
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Bahija Jallal, Ph.D.Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Travis CoyChief Financial Officer
FY2025 (Dec)
1 year
David Berman, M.D., Ph.D.Former Executive Vice President, Head of Research & Development
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Tina St. LegerChief Human Resources Officer
FY2024 (Dec)
FY2023 (Dec)
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $11.4M. The CEO of Immunocore Holdings was paid $10.9M, 5% below the median.

  1. 1TG Therapeutics
  2. 2Revolution Medicines
  3. 3Ionis Pharmaceuticals
  4. 4Immunocore Holdings
  5. 5IDEAYA Biosciences
  6. 6Vir Biotechnology
  7. 7Beam Therapeutics
  8. 8Amicus TherapeuticsNot disclosed
  9. 9Apellis PharmaceuticalsNot disclosed
  10. 10Arcus BiosciencesNot disclosed
  11. 11Arrowhead PharmaceuticalsNot disclosed
  12. 12ArvinasNot disclosed
  13. 13Axsome TherapeuticsNot disclosed
  14. 14Bicycle TherapeuticsNot disclosed
  15. 15Blueprint MedicinesNot disclosed
  16. 16Galapagos NVNot disclosed
  17. 17ImmaticsNot disclosed
  18. 18Intra-Cellular TherapiesNot disclosed
  19. 19Legend BiotechNot disclosed
  20. 20Mirium PharmaceuticalsNot disclosed
  21. 21XencorNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.